The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models.

ABSTRACT:

Background

Novel therapeutics are urgently needed for high-grade serous ovarian cancer (HGSOC). We identified the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a therapeutic target. NBE-002, an antibody-drug conjugate (ADC) consisting of a humanised anti-ROR1 antibody, huXBR1-402, linked to a highly potent anthracycline-derivative (PNU), has activity in ROR1-positive haematologic malignancies.

Objectives

This study explored the anti-cancer effects of NBE-002 alone and in combination with standard HGSOC therapies, carboplatin, paclitaxel and olaparib.

Design

A ROR1-ADC was tested in cell lines and in vivo models of HGSOC.

Methods

Different ROR1-targeting antibodies and payload compositions were constructed and tested in vitro. The dose

SUBMITTER: Liu D 

PROVIDER: S-EPMC12034953 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature